hsa-mir-3609: Hsa-mir-3609 is a microRNA that has been reported to have inhibitory effects on tumor proliferation, migration, stemness, and tumor-intrinsic PD-L1 expression in triple-negative breast cancer (TNBC) cells [PMC9659572]. It is one of the most upregulated microRNAs in TNBC cells and maps to chromosome 7 [PMC6541642]. Hsa-mir-3609 has been found to induce a significant reduction in the levels of CDK1 protein [PMC6541642]. It contains predictive canonical binding sites on the CDK1 mRNA 3’UTR and is involved in downregulating CDK1 expression [PMC6541642]. Hsa-mir-3609 has also been identified as one of the differentially expressed miRNAs in blood samples of patients with locally advanced breast cancer compared to healthy controls [PMC9727336]. In addition, hsa-mir-3609 has been found to be dysregulated in CD4+ T cells and is abundant only in this cell type [PMC9031252]. It is also one of the hub miRNAs identified in pancreatic cancer and polycystic ovary syndrome (PCOS) studies [PMC8350636] [PMC8538251]. Furthermore, hsa-mir-3609 has been shown to be upregulated only in a good response group compared to controls in achalasia patients [PMC8313935]. Overall, hsa-mir-3609 plays a role in various biological processes and may have potential implications for cancer diagnosis and treatment.